ALX ONCOLOGY HOLDINGS INC (ALXO)
D
Pipeline Grade
Financial Position (from SEC Filings)
$32.4M
Cash & Equivalents
$18.7M
Quarterly Burn Rate
5 mo
Est. Cash Runway
$286M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-06-01 | Phase1 Readout | — |
Active Clinical Trials (7)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05002127 | A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) | PHASE3 | Active Not Recruiting | 127 |
| NCT05467670 | Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platin... | PHASE2 | Active Not Recruiting | 16 |
| NCT07007559 | ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast C... | PHASE2 | Recruiting | 120 |
| NCT05167409 | A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorect... | PHASE2 | Active Not Recruiting | 48 |
| NCT04675294 | Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (A... | PHASE2 | Active Not Recruiting | 189 |
| NCT04675333 | Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous ... | PHASE2 | Active Not Recruiting | 172 |
| NCT07085091 | A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors | PHASE1 | Recruiting | 170 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.